Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
522 Quantitative proteomic profiling of KZR-540, a novel small molecule oral Sec61 inhibitor that selectively inhibits PD-1 expression
Compose a Response to This Article
Other responses
No responses have been published for this article.
